Conference Coverage

Interrupting oral anticoagulation in AF carries high thromboembolic cost

Publish date: November 1, 2016

 

AT THE ESC CONGRESS 2016

Pages

Recommended Reading

Andexanet controlled factor Xa inhibitor–related bleeding
MDedge Cardiology
ENSURE-AF trial supports edoxaban for electrical cardioversion
MDedge Cardiology
Commentary: INR instability in the NOAC era
MDedge Cardiology
Trials offer lessons despite negative primary endpoints
MDedge Cardiology
NOACs outpace warfarin for afib anticoagulation
MDedge Cardiology
Rivaroxaban linked to more bleeding compared with dabigatran in elderly patients with nonvalvular AF
MDedge Cardiology
FDA reaffirms rivaroxaban’s atrial fib efficacy in ROCKET AF
MDedge Cardiology
Beta-blockers curb death risk in patients with primary prevention ICD
MDedge Cardiology
Joint European atrial fibrillation guidelines break new ground
MDedge Cardiology
Adaptive servo ventilation cuts atrial fib burden
MDedge Cardiology